BHLHE22 Expression in Breast Cancer : a TCGA Database Analysis

Abstract

Breast cancer (BC), an estrogen-dependent malignancy, hinge on the mitogenic outcome of estrogen in multiplying tumorigenesis and tumor growth. BC reported as one of the most common and death caused cancer in female. The basic helix-loop-helix family member e22 (BHLHE22), an intronless gene,is critical regulator for genes expression and have been linked to estrogen-dependent type of endometrial cancer. The aim of this study is to comprehensively analize the expression of BHLHE22 in breast cancer patients from TCGA database. BHLHE22 genotype data and clinical information about BC patients were obtained using Cbiom, XENA, and ATLAS data from the TCGA breast cancer database. The R studio and Medcalc software was used to analyze statistical data and create graphs. We found that BHLHE22 is a breast cancer survival and immunology-related gene. Different associations between BHLHE22 and survival were identified in this investigation, and it was demonstrated that BHLHE22 gene expression increased in radiotherapy-treated breast cancer patients. BHLHE22 is an immune system gene, and the link between it and the BHLHE22 gene decreases in malignancies at an advanced stage. Therefore, in order to advance research on breast cancer patients, it is vital to consider ways to improve the immune systems of breast cancer patients by examining the specific function of the BHLHE22 gene. BHLHE22 has the ability to influence immune-related pathways and the immunological status of the BC microenvironmentced stage. Therefore, in order to advance research on breast cancer patients, it is vital to consider ways to improve the immune systems of breast cancer patients by examining the specific function of the BHLHE22 gene. More research is required on the immunomodulatory role of BHLHE22 in cancer.